Related Experiment Video

Updated: Mar 28, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K

The effects of bufadienolides on HER2 overexpressing breast cancer cells

Tianjiao Wang1, Lin Mu2, Haifeng Jin1

  • 1Institute of Cancer Stem Cell, Dalian Medical University Cancer Center, Dalian, China.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|December 15, 2015
PubMed

Insights

Arenobufagin and bufalin inhibit HER2-positive breast cancer cell growth by impacting key survival pathways. These compounds may enhance tamoxifen therapy effectiveness, offering new adjuvant treatment options.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • HER2 proto-oncogene amplification drives aggressive breast cancer, often leading to tamoxifen resistance and poorer survival.
  • Cardiac glycoside derivatives, arenobufagin and bufalin, are investigated for their therapeutic potential.

Purpose of the Study:

  • To evaluate the anti-cancer effects of arenobufagin and bufalin on HER2-overexpressing breast cancer cells.
  • To elucidate the underlying mechanisms, including impacts on HER2 downstream signaling pathways.

Main Methods:

  • Assessing the effects of arenobufagin and bufalin on cell proliferation and survival.
  • Analyzing the modulation of key proteins in HER2 downstream pathways (SRC-1, SRC-3, E2F1, p-AKT, p-ERK).
  • Investigating the combined effects with tamoxifen.

Main Results:

  • Arenobufagin and bufalin significantly inhibited proliferation and survival in HER2-overexpressing breast cancer cells.
  • These agents reduced levels of SRC-1, SRC-3, E2F1, phosphorylated AKT, and ERK.
  • Low-dose combinations of bufadienolides with tamoxifen enhanced tamoxifen's inhibitory effects.

Conclusions:

  • Arenobufagin and bufalin demonstrate potent anti-cancer activity against HER2-positive breast cancer.
  • These compounds modulate critical signaling pathways involved in cancer cell survival and proliferation.
  • Arenobufagin and bufalin show promise as potential adjuvant therapies for HER2-overexpressing breast cancer.
Keywords:
Breast cancerHER2SRC-1SRC-3

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K